Tessera Defense and Homeland Security
Logotype for Tessera Defense and Homeland Security Inc

Tessera Defense and Homeland Security (HLSQ) investor relations material

Tessera Defense and Homeland Security Proxy filing summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Tessera Defense and Homeland Security Inc
Proxy filing summary8 Oct, 2026

Executive summary

  • October 7, 2026 employment agreements set compensation for CEO Michael Oster and CFO David Rokach; equity awards are conditional on stockholder approval of an expanded 2026 Equity Incentive Plan.

  • A Special Meeting is scheduled for October 20, 2026 to consider increasing plan shares from 685,000 to 6,000,000; NYSE American approval to list underlying shares is also required.

Voting matters and shareholder proposals

  • Stockholders are asked to approve the plan amendment increasing shares reserved for issuance from 685,000 to 6,000,000 at the October 20, 2026 Special Meeting.

  • The proposed amendment is a condition to Oster's and Rokach's specified equity awards; the awards also require applicable corporate approvals, and listing approval for the underlying shares.

Board of directors and corporate governance

  • The Compensation Committee and Board approved Oster's and Rokach's agreements on October 7, 2026; each executive is excluded from discussion and voting on approval of his own agreement.

  • Oster reports to the boards of the parent and Israeli subsidiary; his duties include strategy, risk management, financial reporting, compliance and investor relations.

  • Rokach serves as CFO, reports to Oster at the subsidiary, and shares board oversight; Oster is also acting Chairman of subsidiary boards.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Tessera Defense and Homeland Security earnings date

Logotype for Tessera Defense and Homeland Security Inc
Q3 202627 Nov, 2026
Tessera Defense and Homeland Security
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Tessera Defense and Homeland Security earnings date

Logotype for Tessera Defense and Homeland Security Inc
Q3 202627 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

BiomX Inc. is a clinical-stage biotechnology company specializing in the development of both natural and engineered phage therapies. These therapies are designed to target and eliminate specific harmful bacteria, particularly those involved in chronic diseases. The company's key focus areas include conditions like cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX utilizes its proprietary phage technology to discover and validate bacterial targets, subsequently customizing phage compositions to combat these targets effectively. The company is headquartered in Ness Ziona, Israel, and its shares are listed on the NYSE.